-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Downgrades Sage Therapeutics to Neutral, Lowers Price Target to $8.5

Benzinga·06/17/2025 15:22:14
Listen to the news
Piper Sandler analyst David Amsellem downgrades Sage Therapeutics (NASDAQ:SAGE) from Overweight to Neutral and lowers the price target from $9 to $8.5.